HypertensionRandomised controlled trial
Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension
- Randomised controlled trial
- multicentre
- double-blind
- placebo-controlled
Authors' conclusion
Lorundrostat was associated with greater reductions in 24-hour average blood pressure than placebo in participants with uncontrolled and treatment-resistant hypertension.
Study context
- Population
- Uncontrolled hypertension on 2–5 antihypertensive drugs (office BP ≥140/90 mm Hg), 24-h ambulatory BP ≥130/80 mm Hg after a 3-week standardized regimen
- Participants
- 285 participants
- Comparison
- Lorundrostat vs placebo
- Stable-dosen = 94
- Dose-adjustmentn = 96
- Placebon = 95reference
- Primary endpoint
- Change in 24-h average SBP, as least-squares mean difference from placebo in each lorundrostat group
- Follow-up
- Baseline to week 12
Primary result
As reported in the abstract
Change in 24-h average SBP · 12 weeks
Stable-dose
−15.4
least-squares mean change · mm Hg
Dose-adjustment
−13.9
least-squares mean change · mm Hg
Placebo
−7.4
least-squares mean change · mm Hg
Each group vs placeboPlacebo-adjusted change, mm Hg (97.5% CI)
Stable-dose
−7.9(−13.3 to −2.6)
Dose-adjustment
−6.5(−11.8 to −1.2)
Secondary outcomes
| Outcome | placebo-adjusted change (mm Hg) (95% CI) | |
|---|---|---|
| Change in 24-h average SBP, combined lorundrostat groups (key secondary) · baseline to week 4 | −5.3 (−8.4 to −2.3) | |
| −10−505Difference, mm Hg (linear scale) |
Safety
| Outcome | Stable-dose | Dose-adjustment | Placebo |
|---|---|---|---|
| Potassium >6.0 mmol/L | 5% | 7% | 0 events |
Original publication
Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension. N Engl J Med. Published 23 April 2025. doi:10.1056/nejmoa2501440
Summarised from the published abstract; every number is checked against it